Zhitong Finance App News, Baokang Shiyun-B (02592.HK) announced that on July 14, 2026, it has completed the review period for the CBT-358 new drug clinical trial application (new drug clinical trial application) submitted to the US Food and Drug Administration (US Drug Administration) on May 21, 2026. The US Drug Administration has completed the safety review of the new drug clinical trial application and has no objection to the proposed clinical study.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.